Insider Selling: Trevor Jones Sells 2,000 Shares of Allergan Stock (AGN)
Allergan (NYSE:AGN) Director Trevor Jones unloaded 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $90.14, for a total transaction of $180,280.00. Following the transaction, the director now directly owns 7,142 shares of the company’s stock, valued at approximately $643,780. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Allergan (NYSE:AGN) traded up 0.11% on Wednesday, hitting $89.81. The stock had a trading volume of 2,743,995 shares. Allergan has a 1-year low of $81.33 and a 1-year high of $116.45. The stock’s 50-day moving average is $89.74 and its 200-day moving average is $96.20. The company has a market cap of $26.661 billion and a price-to-earnings ratio of 28.85.
Allergan (NYSE:AGN) last announced its earnings results on Wednesday, July 31st. The company reported $1.22 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.20 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter last year, the company posted $1.07 earnings per share. Allergan’s revenue was up 10.2% compared to the same quarter last year. On average, analysts predict that Allergan will post $4.76 earnings per share for the current fiscal year.
AGN has been the subject of a number of recent research reports. Analysts at Credit Suisse initiated coverage on shares of Allergan in a research note to investors on Tuesday, October 8th. They set an “outperform” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Allergan in a research note to investors on Monday, September 16th. They now have a $93.00 price target on the stock. Finally, analysts at JMP Securities cut their price target on shares of Allergan from $115.00 to $110.00 in a research note to investors on Thursday, August 1st. They now have a “market outperform” rating on the stock. Eleven research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $107.16.
Allergan, Inc, is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.